SCHEMBL7336457

SCHEMBL7336457

Cc1ccc(NC(=O)c2ccc3cc(C=NN)ccc3c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 9/20 0.53
▸ RAB9A P51151 9/20 0.53
▸ ENPP2 Q13822 1/20 0.52
▸ PLAU P00749 5/20 0.48
▸ F2 P00734 2/20 0.48
▸ PLG P00747 2/20 0.48
▸ KLKB1 P03952 2/20 0.48
▸ PRSS1 P07477 2/20 0.48
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ TP53 P04637 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7340329 0.88 PLAU (0.63) NPC1RAB9APLAUF2PLG
SCHEMBL7345579 0.86 PLAU (0.65) NPC1RAB9APLAUF2PLG
SCHEMBL7337325 0.85 PLAU (0.58) NPC1RAB9AENPP2PLAUF2
SCHEMBL7343089 0.85 PLAU (0.67) NPC1RAB9APLAUF2PLG
SCHEMBL7343081 0.85 PLAU (0.67) NPC1RAB9APLAUF2PLG
SCHEMBL7337311 0.85 PLAU (0.58) NPC1RAB9AENPP2PLAUF2
SCHEMBL7345240 0.85 PLAU (0.64) NPC1RAB9AENPP2PLAUF2
SCHEMBL7335937 0.85 DEGS1 (0.57) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL7346207 0.84 BCAT2 (0.47) NPC1RAB9APLAUF2PLG
SCHEMBL7337258 0.83 IKBKB (0.56) NPC1RAB9APLAUPLGMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 — — US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 — — US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 — — US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 — — EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 NPC1 2478/4885RAB9A 2845/4885ENPP2 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback